Temporomandibular Joint in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis Clinical Trial

Official title:

Temporomandibular Joint in Patients With Rheumatoid Arthritis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06134726
• Other study ID #: BX63413,2021
• Status: Completed
• Start date: January 15, 2021
• Est. completion date: January 15, 2023

Study information

• Verified date: November 2023
• Source: Syrian Private University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

the investigators study aimed to evaluate temporomandibular joint involvement in rheumatoid arthritis patients and healthy individuals 142 participants were recruited in two groups: 72 patients with Rheumatoid Arthritis (RA), and 70 healthy controls. All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies. TMD diagnosis was determined according to the standardized and validated diagnostic criteria for TMD (DC/TMD): myalgia, arthralgia, articular disc, displacement, degenerative joint disease, and headache attributed to TMD. Bruxism, a probable sleep and/or awake bruxism diagnosis was determined based on self-report and several clinical findings.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 142
• Est. completion date: January 15, 2023
• Est. primary completion date: January 1, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 35 Years to 50 Years

Eligibility

• Inclusion criteria included:

• age > 18 years old

• individuals who had a minimum of 12 natural teeth.

• Exclusion criteria

• included: trauma or surgery on the jaw

• facial nerve paralysis

• tooth implant

• scleroderma

• cerebrovascular accident

• schizophrenia

• steroid injection within the last six months.

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Joint Diseases
• Rheumatoid Arthritis
• Temporomandibular Joint Disorders
• Temporomandibular Joint Dysfunction Syndrome

Intervention

Diagnostic Test:
• seropositivity of rheumatoid factor
All participants were tested for seropositivity of rheumatoid factor and anticitrullinated protein antibodies

Locations

Country	Name	City	State
Syrian Arab Republic	Faculty of Medicine, Damascus University, Syria	Damascus

Sponsors (1)

Lead Sponsor	Collaborator
Syrian Private University

Country where clinical trial is conducted

Syrian Arab Republic, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of patients with prevalence of TMD	patients were interviewed, filled out the questionnaire, and examined	2 years
Primary	Number of patients with TMD-pain diagnoses	patients were interviewed, filled out the questionnaire, and examined	2 years